Elisa Agostinetto
@elisaagostinetto.bsky.social
Medical Oncologist and Researcher in Breast Cancer
📍Institut Jules Bordet, Brussels🇧🇪
📍Institut Jules Bordet, Brussels🇧🇪
I am thrilled to start the #ESMO Leadership Program 2025/26 with such an amazing class of colleagues from all over the world! 🌎
Truly honored for being selected for this prestigious program and looking forward to #ESMO25 to start this journey together🚀
@myesmo.bsky.social @oncoalert.bsky.social
Truly honored for being selected for this prestigious program and looking forward to #ESMO25 to start this journey together🚀
@myesmo.bsky.social @oncoalert.bsky.social
September 17, 2025 at 8:52 AM
I am thrilled to start the #ESMO Leadership Program 2025/26 with such an amazing class of colleagues from all over the world! 🌎
Truly honored for being selected for this prestigious program and looking forward to #ESMO25 to start this journey together🚀
@myesmo.bsky.social @oncoalert.bsky.social
Truly honored for being selected for this prestigious program and looking forward to #ESMO25 to start this journey together🚀
@myesmo.bsky.social @oncoalert.bsky.social
Are you a young oncologist attending #ASCO25?
Join us on Monday, June 2 to talk about the Keys to Success for the Early Career Oncologist! 🔑 💫
Check here the sessions scheduled at the Trainee & Early Career Lounge: cdn.bfldr.com/KOIHB2Q3/as/...
@oncoalert.bsky.social
@ascocancer.bsky.social
Join us on Monday, June 2 to talk about the Keys to Success for the Early Career Oncologist! 🔑 💫
Check here the sessions scheduled at the Trainee & Early Career Lounge: cdn.bfldr.com/KOIHB2Q3/as/...
@oncoalert.bsky.social
@ascocancer.bsky.social
May 29, 2025 at 7:02 AM
Are you a young oncologist attending #ASCO25?
Join us on Monday, June 2 to talk about the Keys to Success for the Early Career Oncologist! 🔑 💫
Check here the sessions scheduled at the Trainee & Early Career Lounge: cdn.bfldr.com/KOIHB2Q3/as/...
@oncoalert.bsky.social
@ascocancer.bsky.social
Join us on Monday, June 2 to talk about the Keys to Success for the Early Career Oncologist! 🔑 💫
Check here the sessions scheduled at the Trainee & Early Career Lounge: cdn.bfldr.com/KOIHB2Q3/as/...
@oncoalert.bsky.social
@ascocancer.bsky.social
I am so grateful that our work has been awarded with a #ConquerCancer #ASCO Merit Award! 💫
Proud to be on this list for the third time, a big thank goes to my mentors and co-authors - Looking forward to presenting our work in Chicago!🇧🇪✈️🇺🇸
@oncoalert.bsky.social
Proud to be on this list for the third time, a big thank goes to my mentors and co-authors - Looking forward to presenting our work in Chicago!🇧🇪✈️🇺🇸
@oncoalert.bsky.social
April 25, 2025 at 1:49 PM
I am so grateful that our work has been awarded with a #ConquerCancer #ASCO Merit Award! 💫
Proud to be on this list for the third time, a big thank goes to my mentors and co-authors - Looking forward to presenting our work in Chicago!🇧🇪✈️🇺🇸
@oncoalert.bsky.social
Proud to be on this list for the third time, a big thank goes to my mentors and co-authors - Looking forward to presenting our work in Chicago!🇧🇪✈️🇺🇸
@oncoalert.bsky.social
Extended adjuvant endocrine therapy for HR+/HER2-neg #breastcancer is a highly debated topic
Supporting the choice of prolonged treatment means balancing the QoL against the costs of toxicity
In this review we address this topic👇🏻
@oncoalert.bsky.social
www.sciencedirect.com/science/arti...
Supporting the choice of prolonged treatment means balancing the QoL against the costs of toxicity
In this review we address this topic👇🏻
@oncoalert.bsky.social
www.sciencedirect.com/science/arti...
April 24, 2025 at 1:16 PM
Extended adjuvant endocrine therapy for HR+/HER2-neg #breastcancer is a highly debated topic
Supporting the choice of prolonged treatment means balancing the QoL against the costs of toxicity
In this review we address this topic👇🏻
@oncoalert.bsky.social
www.sciencedirect.com/science/arti...
Supporting the choice of prolonged treatment means balancing the QoL against the costs of toxicity
In this review we address this topic👇🏻
@oncoalert.bsky.social
www.sciencedirect.com/science/arti...
I am very proud to see published in #JCO the results of our global collaboration🌎 led by @matteolambe showing different clinical behavior of breast cancer in young BRCA1 and BRCA2 carriers, and the impact of timing of genetic testing on prognosis
@oncoalert.bsky.social
ascopubs.org/doi/10.1200/...
@oncoalert.bsky.social
ascopubs.org/doi/10.1200/...
February 25, 2025 at 7:08 AM
I am very proud to see published in #JCO the results of our global collaboration🌎 led by @matteolambe showing different clinical behavior of breast cancer in young BRCA1 and BRCA2 carriers, and the impact of timing of genetic testing on prognosis
@oncoalert.bsky.social
ascopubs.org/doi/10.1200/...
@oncoalert.bsky.social
ascopubs.org/doi/10.1200/...
Today the Office of the US Surgeon General advisory released a report on Alcohol and Cancer Risk 🍷
Consuming alcohol ⬆️ the risk of at least 7 types of cancer, including #breastcancer
@oncoalert.bsky.social
www.hhs.gov/surgeongener...
Consuming alcohol ⬆️ the risk of at least 7 types of cancer, including #breastcancer
@oncoalert.bsky.social
www.hhs.gov/surgeongener...
January 4, 2025 at 10:38 AM
Today the Office of the US Surgeon General advisory released a report on Alcohol and Cancer Risk 🍷
Consuming alcohol ⬆️ the risk of at least 7 types of cancer, including #breastcancer
@oncoalert.bsky.social
www.hhs.gov/surgeongener...
Consuming alcohol ⬆️ the risk of at least 7 types of cancer, including #breastcancer
@oncoalert.bsky.social
www.hhs.gov/surgeongener...
At #SABCS24 the updated survival results of the OLYMPIA trial were presented
@FrancoisDuhoux and I discussed with @Medi_Mix these clinically relevant data and implications for daily clinical practice ⬇️
@oncoalert.bsky.social
medimix.be/onco/sabcs-s...
@FrancoisDuhoux and I discussed with @Medi_Mix these clinically relevant data and implications for daily clinical practice ⬇️
@oncoalert.bsky.social
medimix.be/onco/sabcs-s...
January 4, 2025 at 10:35 AM
At #SABCS24 the updated survival results of the OLYMPIA trial were presented
@FrancoisDuhoux and I discussed with @Medi_Mix these clinically relevant data and implications for daily clinical practice ⬇️
@oncoalert.bsky.social
medimix.be/onco/sabcs-s...
@FrancoisDuhoux and I discussed with @Medi_Mix these clinically relevant data and implications for daily clinical practice ⬇️
@oncoalert.bsky.social
medimix.be/onco/sabcs-s...
#SABCS24 came to its end, and I bring home great memories:
- my first #EarlyInvestigatorAward 💫
- seing presented at the general session (by @mattelambe) new results of our collaborative BRCA BCY group
- ❤️ to all the amazing friends with whom I share this journey
@oncoalert.bsky.social
- my first #EarlyInvestigatorAward 💫
- seing presented at the general session (by @mattelambe) new results of our collaborative BRCA BCY group
- ❤️ to all the amazing friends with whom I share this journey
@oncoalert.bsky.social
December 14, 2024 at 4:55 AM
#SABCS24 came to its end, and I bring home great memories:
- my first #EarlyInvestigatorAward 💫
- seing presented at the general session (by @mattelambe) new results of our collaborative BRCA BCY group
- ❤️ to all the amazing friends with whom I share this journey
@oncoalert.bsky.social
- my first #EarlyInvestigatorAward 💫
- seing presented at the general session (by @mattelambe) new results of our collaborative BRCA BCY group
- ❤️ to all the amazing friends with whom I share this journey
@oncoalert.bsky.social
Also this year I can confirm that #SABCS is my fav congress of the year💕
I am so proud to have received an #EarlyInvestigatorAward for the study we presented today, and to share this achievement with the entire team of wonderful colleagues and friends!
@oncoalert.bsky.social
@sabcs.bsky.social
I am so proud to have received an #EarlyInvestigatorAward for the study we presented today, and to share this achievement with the entire team of wonderful colleagues and friends!
@oncoalert.bsky.social
@sabcs.bsky.social
December 12, 2024 at 10:51 PM
Also this year I can confirm that #SABCS is my fav congress of the year💕
I am so proud to have received an #EarlyInvestigatorAward for the study we presented today, and to share this achievement with the entire team of wonderful colleagues and friends!
@oncoalert.bsky.social
@sabcs.bsky.social
I am so proud to have received an #EarlyInvestigatorAward for the study we presented today, and to share this achievement with the entire team of wonderful colleagues and friends!
@oncoalert.bsky.social
@sabcs.bsky.social
General session 1️⃣ at #SABCS24 starts with the very much awaited results of EMBER-3
3 co-primary endpoints:
1️⃣In ESR1-mut pts, imlunestrant ⬆️ PFS vs. ET SoC
2️⃣No significant difference in all pts
3️⃣Imlu + abema ⬆️ PFS (vs. Imlu) in all pts, regardless of ESR1-mut
@oncoalert.bsky.social
3 co-primary endpoints:
1️⃣In ESR1-mut pts, imlunestrant ⬆️ PFS vs. ET SoC
2️⃣No significant difference in all pts
3️⃣Imlu + abema ⬆️ PFS (vs. Imlu) in all pts, regardless of ESR1-mut
@oncoalert.bsky.social
December 11, 2024 at 3:32 PM
General session 1️⃣ at #SABCS24 starts with the very much awaited results of EMBER-3
3 co-primary endpoints:
1️⃣In ESR1-mut pts, imlunestrant ⬆️ PFS vs. ET SoC
2️⃣No significant difference in all pts
3️⃣Imlu + abema ⬆️ PFS (vs. Imlu) in all pts, regardless of ESR1-mut
@oncoalert.bsky.social
3 co-primary endpoints:
1️⃣In ESR1-mut pts, imlunestrant ⬆️ PFS vs. ET SoC
2️⃣No significant difference in all pts
3️⃣Imlu + abema ⬆️ PFS (vs. Imlu) in all pts, regardless of ESR1-mut
@oncoalert.bsky.social
@vkaklamani.bsky.social opens the General Session 1️⃣ at #SABCS24 with the key meeting highlights ⬇️
@oncoalert.bsky.social
@oncoalert.bsky.social
December 11, 2024 at 2:36 PM
@vkaklamani.bsky.social opens the General Session 1️⃣ at #SABCS24 with the key meeting highlights ⬇️
@oncoalert.bsky.social
@oncoalert.bsky.social
At #SABCS24 LBA session - @dradityabardia on Efficacy and Safety of T-DXd by Pace of Disease Progression on Prior Endocrine-Based Therapy in DESTINY-Breast06
T-DXd ⬆️PFS regardless of time to progression on 1st line CDK4/6i+ET or type of endocrine resistance
@oncoalert.bsky.social
T-DXd ⬆️PFS regardless of time to progression on 1st line CDK4/6i+ET or type of endocrine resistance
@oncoalert.bsky.social
December 11, 2024 at 12:38 AM
At #SABCS24 LBA session - @dradityabardia on Efficacy and Safety of T-DXd by Pace of Disease Progression on Prior Endocrine-Based Therapy in DESTINY-Breast06
T-DXd ⬆️PFS regardless of time to progression on 1st line CDK4/6i+ET or type of endocrine resistance
@oncoalert.bsky.social
T-DXd ⬆️PFS regardless of time to progression on 1st line CDK4/6i+ET or type of endocrine resistance
@oncoalert.bsky.social
At #SABCS24 LBA session - @LoiblSibylle on the PADMA trial comparing 1st line ET + Palbo vs Standard Mono-CT in High Risk HER2-/HR+ metastatic BC and indication for CT
⬆️TTF and PFS w/palbo+ET
Reassuring data supporting 1st line CDK4/6i+ET as SoC
@oncoalert.bsky.social
⬆️TTF and PFS w/palbo+ET
Reassuring data supporting 1st line CDK4/6i+ET as SoC
@oncoalert.bsky.social
December 11, 2024 at 12:26 AM
At #SABCS24 LBA session - @LoiblSibylle on the PADMA trial comparing 1st line ET + Palbo vs Standard Mono-CT in High Risk HER2-/HR+ metastatic BC and indication for CT
⬆️TTF and PFS w/palbo+ET
Reassuring data supporting 1st line CDK4/6i+ET as SoC
@oncoalert.bsky.social
⬆️TTF and PFS w/palbo+ET
Reassuring data supporting 1st line CDK4/6i+ET as SoC
@oncoalert.bsky.social
At #SABCS24 LBA session - The MARGOT trial comparing neoadjuvant Paclitaxel/Margetuximab/Pertuzumab (TMP) vs Paclitaxel/Trastuzumab/Pertuzumab (THP) in Stage II-III HER2+ BC w/CD16A FF/FV
No difference in pCR
Survival still immature
Similar safety but ⬆️IRR w/TMP
@oncoalert.bsky.social
No difference in pCR
Survival still immature
Similar safety but ⬆️IRR w/TMP
@oncoalert.bsky.social
December 11, 2024 at 12:20 AM
At #SABCS24 LBA session - The MARGOT trial comparing neoadjuvant Paclitaxel/Margetuximab/Pertuzumab (TMP) vs Paclitaxel/Trastuzumab/Pertuzumab (THP) in Stage II-III HER2+ BC w/CD16A FF/FV
No difference in pCR
Survival still immature
Similar safety but ⬆️IRR w/TMP
@oncoalert.bsky.social
No difference in pCR
Survival still immature
Similar safety but ⬆️IRR w/TMP
@oncoalert.bsky.social
At #SABCS24 LBA session - an EBCTCG meta-analysis explored immediate vs deferral surgery in women 70+ with operable breast cancer
Reduced local recurrence, distant recurrence and BC-mortality in the immediate surgery group
@oncoalert.bsky.social
Reduced local recurrence, distant recurrence and BC-mortality in the immediate surgery group
@oncoalert.bsky.social
December 11, 2024 at 12:11 AM
At #SABCS24 LBA session - an EBCTCG meta-analysis explored immediate vs deferral surgery in women 70+ with operable breast cancer
Reduced local recurrence, distant recurrence and BC-mortality in the immediate surgery group
@oncoalert.bsky.social
Reduced local recurrence, distant recurrence and BC-mortality in the immediate surgery group
@oncoalert.bsky.social
At #SABCS24 session chaired by @matteolambe on breast cancer in young women
Prudence Francis talks about ovarian suppression - very young women should be considered for OFS, and absolute benefit is correlated to baseline recurrence risk
@oncoalert.bsky.social
Prudence Francis talks about ovarian suppression - very young women should be considered for OFS, and absolute benefit is correlated to baseline recurrence risk
@oncoalert.bsky.social
December 10, 2024 at 11:00 PM
At #SABCS24 session chaired by @matteolambe on breast cancer in young women
Prudence Francis talks about ovarian suppression - very young women should be considered for OFS, and absolute benefit is correlated to baseline recurrence risk
@oncoalert.bsky.social
Prudence Francis talks about ovarian suppression - very young women should be considered for OFS, and absolute benefit is correlated to baseline recurrence risk
@oncoalert.bsky.social
At #SABCS24 translational workshop Christos Sotiriou talks about TNBC Inter and intra-patient heterogeneity, and implication for treatments and outcomes
@oncoalert.bsky.social
@oncoalert.bsky.social
December 10, 2024 at 9:13 PM
At #SABCS24 translational workshop Christos Sotiriou talks about TNBC Inter and intra-patient heterogeneity, and implication for treatments and outcomes
@oncoalert.bsky.social
@oncoalert.bsky.social
#SABCS24 opens with a useful session for early investigators on career development 🧗 💫
@stolaney1.bsky.social talks about tips to successfully apply for funding:
1️⃣Identify the right project
2️⃣Strategy development
3️⃣Acknowledge foundation grants!
Team work is 🔑
@oncoalert.bsky.social
@stolaney1.bsky.social talks about tips to successfully apply for funding:
1️⃣Identify the right project
2️⃣Strategy development
3️⃣Acknowledge foundation grants!
Team work is 🔑
@oncoalert.bsky.social
December 10, 2024 at 6:30 PM
#SABCS24 opens with a useful session for early investigators on career development 🧗 💫
@stolaney1.bsky.social talks about tips to successfully apply for funding:
1️⃣Identify the right project
2️⃣Strategy development
3️⃣Acknowledge foundation grants!
Team work is 🔑
@oncoalert.bsky.social
@stolaney1.bsky.social talks about tips to successfully apply for funding:
1️⃣Identify the right project
2️⃣Strategy development
3️⃣Acknowledge foundation grants!
Team work is 🔑
@oncoalert.bsky.social
Adjuvant ribociclib has been approved by EMA for HR+/HER2- early breast cancer, based on the results of NATALEE
Industry press release⬇️
@oncoalert.bsky.social
www.novartis.com/news/media-r...
Industry press release⬇️
@oncoalert.bsky.social
www.novartis.com/news/media-r...
November 29, 2024 at 7:51 AM
Adjuvant ribociclib has been approved by EMA for HR+/HER2- early breast cancer, based on the results of NATALEE
Industry press release⬇️
@oncoalert.bsky.social
www.novartis.com/news/media-r...
Industry press release⬇️
@oncoalert.bsky.social
www.novartis.com/news/media-r...
A full room for the Young Cancer Professionals meeting at the #EropeanCancerSummit 🇪🇺
Many opportunities and upcoming projects to give voice to the youngest generations of cancer professionals and improve cancer care💪🏻
Join us! ⬇️
europeancancer.org/ycp
@oncoalert.bsky.social @ec.europa.eu
Many opportunities and upcoming projects to give voice to the youngest generations of cancer professionals and improve cancer care💪🏻
Join us! ⬇️
europeancancer.org/ycp
@oncoalert.bsky.social @ec.europa.eu
November 20, 2024 at 2:44 PM
A full room for the Young Cancer Professionals meeting at the #EropeanCancerSummit 🇪🇺
Many opportunities and upcoming projects to give voice to the youngest generations of cancer professionals and improve cancer care💪🏻
Join us! ⬇️
europeancancer.org/ycp
@oncoalert.bsky.social @ec.europa.eu
Many opportunities and upcoming projects to give voice to the youngest generations of cancer professionals and improve cancer care💪🏻
Join us! ⬇️
europeancancer.org/ycp
@oncoalert.bsky.social @ec.europa.eu